Evidence map›Paper›PMID 41017825›Full record

ArticleComputational and structural biotechnology journal2025

Identification of shared and unique mechanisms of atopic dermatitis and ulcerative colitis by construction and computational analysis of disease maps.

Oxana Lopata, Marcio Luis Acencio, Xinhui Wang, Ahmed Abdelmonem Hemedan, Michael J Chao, Scott A Jelinsky, Florian Tran, Philip Rosenstiel, Andrew Y F Li Yim, Reinhard Schneider and 2 more

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Oxana LopataLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Marcio Luis AcencioLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Xinhui WangLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Ahmed Abdelmonem HemedanLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Michael J ChaoSanofi, Cambridge, MA, USA.
Scott A JelinskyPfizer Inc, Cambridge, MA, USA.
Florian TranDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Philip RosenstielInstitute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
Andrew Y F Li YimTytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
Reinhard SchneiderLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Venkata SatagopamLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Marek OstaszewskiLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) and ulcerative colitis (UC) are immune-mediated inflammatory diseases (IMIDs) with high prevalence and treatment costs. AD mainly affects the skin, while UC targets the colon and rectum, but both are characterised by immune dysregulation driven by aberrant T helper cell activation, persistent barrier dysfunction, genetic predisposition, and environmental triggers. This overlap may explain the link between the two diseases and the increased risk of UC in patients with AD. Both diseases are chronic, progressive, and limited in treatment options, and there is a need for a better understanding of their mechanisms and biomarkers. To address this, we developed disease maps for UC and AD, covering their molecular mechanisms. Here, we present the development and contents of the maps, as well as demonstrate their application in data visualisation and analysis. Our systematic, interactive comparison reveals both common and disease-specific signatures, as well as common pathological pathways. These findings highlight shared biomarkers for predicting progression and therapy outcomes, and opportunities for drug repurposing. The UC and AD disease maps provide a valuable resource for representing and exploring common and distinct mechanisms, helping to advance IMID management from organ-based symptom relief towards mechanism-based treatments.

Indexed as

Atopic dermatitisBiomarkersDisease mapsSystems biologySystems biomedicineUlcerative colitis

Identifiers

PMID41017825
PMCPMC12465054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.